MediciNova Past Earnings Performance
Past criteria checks 0/6
MediciNova has been growing earnings at an average annual rate of 4.2%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 16.5% per year.
Key information
4.2%
Earnings growth rate
8.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 16.5% |
| Return on equity | -13.7% |
| Net Margin | -857.2% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29
MediciNova selected for the Nasdaq Biotechnology Index
Dec 15MediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosis
Nov 25Revenue & Expenses BreakdownBeta
How MediciNova makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -9 | 5 | 6 |
| 30 Sep 23 | 1 | -10 | 6 | 6 |
| 30 Jun 23 | 0 | -12 | 6 | 8 |
| 31 Mar 23 | 0 | -14 | 6 | 9 |
| 31 Dec 22 | 0 | -14 | 5 | 9 |
| 30 Sep 22 | 0 | -13 | 5 | 9 |
| 30 Jun 22 | 0 | -13 | 5 | 9 |
| 31 Mar 22 | 0 | -13 | 5 | 9 |
| 31 Dec 21 | 4 | -10 | 6 | 9 |
| 30 Sep 21 | 4 | -11 | 7 | 9 |
| 30 Jun 21 | 4 | -11 | 7 | 9 |
| 31 Mar 21 | 4 | -11 | 7 | 8 |
| 31 Dec 20 | 0 | -14 | 7 | 7 |
| 30 Sep 20 | 0 | -13 | 6 | 8 |
| 30 Jun 20 | 0 | -12 | 6 | 6 |
| 31 Mar 20 | 0 | -11 | 6 | 6 |
| 31 Dec 19 | 0 | -13 | 8 | 6 |
| 30 Sep 19 | 0 | -11 | 8 | 4 |
| 30 Jun 19 | 0 | -16 | 11 | 6 |
| 31 Mar 19 | 0 | -15 | 10 | 6 |
| 31 Dec 18 | 0 | -15 | 10 | 6 |
| 30 Sep 18 | 0 | -16 | 12 | 7 |
| 30 Jun 18 | 0 | -13 | 10 | 5 |
| 31 Mar 18 | 0 | -13 | 10 | 5 |
| 31 Dec 17 | 0 | -11 | 9 | 4 |
| 30 Sep 17 | 0 | -11 | 7 | 4 |
| 30 Jun 17 | 0 | -10 | 7 | 3 |
| 31 Mar 17 | 0 | -11 | 7 | 3 |
| 31 Dec 16 | 0 | -11 | 7 | 3 |
| 30 Sep 16 | 0 | -12 | 8 | 4 |
| 30 Jun 16 | 0 | -11 | 7 | 4 |
| 31 Mar 16 | 0 | -10 | 7 | 3 |
| 31 Dec 15 | 0 | -9 | 6 | 3 |
| 30 Sep 15 | 0 | -8 | 6 | 3 |
| 30 Jun 15 | 0 | -9 | 6 | 3 |
| 31 Mar 15 | 0 | -9 | 6 | 3 |
| 31 Dec 14 | 0 | -9 | 6 | 3 |
| 30 Sep 14 | 6 | -3 | 6 | 3 |
| 30 Jun 14 | 6 | -3 | 6 | 3 |
| 31 Mar 14 | 6 | -4 | 7 | 3 |
| 31 Dec 13 | 6 | -4 | 7 | 3 |
| 30 Sep 13 | 0 | -10 | 7 | 3 |
| 30 Jun 13 | 0 | -10 | 7 | 3 |
Quality Earnings: MNOV is currently unprofitable.
Growing Profit Margin: MNOV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MNOV is unprofitable, but has reduced losses over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare MNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MNOV has a negative Return on Equity (-13.74%), as it is currently unprofitable.